Yeast as a budding technology in target validation

Nathan Bays; Jonathan Margolis

doi:10.1016/j.ddtec.2004.09.002

Yeast as a budding technology in target validation

Drug Discov Today Technol. 2004 Oct;1(2):157-62. doi: 10.1016/j.ddtec.2004.09.002.

Authors

Nathan Bays¹, Jonathan Margolis²

Affiliations

¹ Exelixis, Inc, 170 Harbor Way, P.O. Box 511, South San Francisco, CA 94083-0511, USA. Electronic address:nbays@mac.com.
² Exelixis, Inc, 170 Harbor Way, P.O. Box 511, South San Francisco, CA 94083-0511, USA. Electronic address:jmargolis@exelixis.com.

PMID: 24981386
DOI: 10.1016/j.ddtec.2004.09.002

Abstract

Yeast biology has yielded major insights into fundamental cellular biology and has served as a remarkable platform for technical innovation. We review how these resources can be applied to the validation of mammalian or anti-fungal drug targets. These approaches range from elucidating synergistic interactions between drugs and targets to facile methods for tracking proteins in the cell or characterization of receptor biology. We also discuss web-based resources that integrate the extensive biochemical, cell biological, and genetic literature exploring the basic biology of these model eukaryotic cells.: